Back

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

Tsuda, M.; Keith, D.; Daniel, C. J.; Pelz, C.; Blise, K. E.; Ozmen, T. Y.; Ozmen, F.; Hawthone, K.; Eng, J. R.; Li, X.; Wang, X.; Zimny, H.; Sivagnanam, S.; Betre, K.; Kirchberger, N.; Chong, B.; Lee, J.; Matter, _.; Smith, A.; Agritelley, E. S.; Waugh, T.; Sannecy, A.; Alarcon, K.; Youm, I.; Protzek, S.; Egger, J.; English, I. A.; Yang, M.; Shah, V. M.; Link, J. M.; Creason, A. L.; Worth, P. J.; Goodyear, S. M.; Chin, K.; Muschler, J. L.; Suciu, C. G.; Corless, C. L.; Cao, S.; Soucek, L.; Kardosh, A.; Coussens, L. M.; Brody, J. R.; Lopez, C. D.; Mills, G. B.; Sears, R. C.

2025-12-15 cancer biology
10.64898/2025.12.12.693851 bioRxiv
Show abstract

Copy number alterations of KRAS, mutated in over 90% of pancreatic ductal adenocarcinomas (PDAC), and MYC occur in 30-40% of PDAC. Here we demonstrate that KRAS and MYC are frequently co-gained and accompanied with worse prognosis in PDAC. In a Window-of-Opportunity clinical trial for metastatic PDAC, serial biopsies and deep multi-omics analyses were utilized to explore resistance mechanisms to MEK inhibition, as a surrogate for KRAS inhibition. Tumors from four of 14 patients showed Ki-67/CA19-9-based biomarker response (BR). Non-BR tumors were enriched for KRAS/MYC co-gain and KRASG12D variant. A transcriptomic signature of BR tumors was inversely correlated with KRASG12D/MYC co-gain in a large PDAC dataset and predictive for KRAS inhibitor response in multiple models. Finally, co-targeting KRAS and MYC was synergistic in KRASG12D/MYC co-gain PDAC. Together, this study provides insight into KRAS inhibitor resistance and supports MYC as an important target to improve patient outcomes in this deadly disease.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.